Table 2.

Characteristics of the study population

Patient Characteristic at BaselineDose Group Based on Epoetin alfa Dose (IU per 2 wk) at Baseline
Zero DoseCategory 1, ≤14,000Category 2, 14,001 to 27,000Category 3, 27,001 to 49,000Category 4 > 49000All
n304554479048336570327,791
Age, yr (SD)54.8 (14.0)61.0 (15.0)61.8 (15.1)60.5 (14.7)58.1 (14.7)60.4 (14.7)
Female gender, n (%)83 (27.3)2252 (40.6)3835 (48.5)4197 (50.3)2908 (51.0)13275 (47.8)
Black race, n (%)128 (42.1)2060 (37.2)3030 (38.3)3548 (42.6)2778 (48.7)11544 (41.5)
Region, n (%)
    Midwest39 (12.8)488 (8.8)758 (9.6)841 (10.1)568 (10.0)2694 (9.7)
    Northeast50 (16.4)927 (16.7)1277 (16.2)1450 (17.4)1111 (19.5)4815 (17.3)
    South184 (60.5)3226 (58.2)4847 (61.3)5265 (63.2)3595 (63.0)17117 (61.6)
    West31 (10.2)903 (16.3)1022 (12.9)780 (9.4)429 (7.5)3165 (11.4)
Primary Cause of ESRD, n (%)
    Diabetes116 (38.2)2630 (47.4)4087 (51.7)4446 (53.3)2875 (50.4)14154 (50.9)
    Hypertension42 (13.8)729 (13.1)1170 (14.8)1343 (16.1)997 (17.5)4281 (15.4)
Dialysis vintage, yr (SD)5.0 (4.8)3.4 (3.8)2.7 (3.3)2.5 (3.4)2.8 (3.6)2.8 (3.6)
Body mass index, kg/m2, mean (SD)28.0 (8.1)26.2 (6.7)26.4 (6.7)27.2 (7.2)28.3 (7.9)27.0 (7.9)
Ferritin, ng/ml, mean (SD)500.8 (322.9)591.8 (360.7)527.4 (341.5)478.7 (343.6)473.3 (351.8)514.2 (351.8)
Hemoglobin, g/dl, mean (SD)12.9 (1.3)12.1 (0.8)11.9 (0.8)11.6 (0.9)11.0 (1.1)11.7 (1.1)
TSAT, %, mean (SD)31.5 (10.4)32.1 (9.7)29.1 (9.2)26.5 (8.9)24.3 (9.3)28.0 (9.3)
Albumin, g/dl, mean (SD)3.9 (0.3)3.9 (0.3)3.8 (0.3)3.8 (0.3)3.7 (0.4)3.8 (0.4)